New strategies for advanced neuroendocrine tumors in the era of targeted therapy

Mei Dong, Alexandria T. Phan, James C. Yao

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Low- to intermediate-grade neuroendocrine tumor (NET) constitutes a group of indolent malignancies that share the capacity for secreting hormones and neuroamines. Until recently, there were few therapeutic options for oncologic control. The PROMID study showed that octreotide long-acting repeatable formulation can delay tumor growth in midgut NETs. And, recent phase III studies showed both everolimus and sunitinib improved progression-free survival in pancreatic NETs, validating the phosphoinositide 3-kinase/Akt/mTOR pathway and angiogenesis as important targets for further advances. Ongoing and planned pivotal studies targeting these pathways in other NET subtypes may widen their therapeutic application. Development of rational combinations may further improve therapeutic outcome. These successes and our improved understanding of the underlying molecular biology are likely to lead to further important advances on the horizon.

Original languageEnglish (US)
Pages (from-to)1830-1836
Number of pages7
JournalClinical Cancer Research
Volume18
Issue number7
DOIs
StatePublished - Apr 1 2012

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New strategies for advanced neuroendocrine tumors in the era of targeted therapy'. Together they form a unique fingerprint.

Cite this